WallStSmart

Butterfly Network Inc (BFLY)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 54987% more annual revenue ($56.69B vs $102.92M). NVS leads profitability with a 22.5% profit margin vs -73.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).

BFLY

Avoid

25

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -2.75

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BFLY.

NVSSignificantly Overvalued (-70.9%)

Margin of Safety

-70.9%

Fair Value

$92.73

Current Price

$158.83

$66.10 premium

UndervaluedFair: $92.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BFLY2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
25.0%8/10

Revenue surging 25.0% year-over-year

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$290.96B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

BFLY4 concerns · Avg: 3.5/10
Price/BookValuation
11.2x4/10

Trading at 11.2x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.73B3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
4.152/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BFLY

The strongest argument for BFLY centers on Debt/Equity, Revenue Growth. Revenue growth of 25.0% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.

Bear Case : BFLY

The primary concerns for BFLY are Price/Book, EPS Growth, Market Cap.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

BFLY profiles as a growth stock while NVS is a value play — different risk/reward profiles.

BFLY carries more volatility with a beta of 2.05 — expect wider price swings.

BFLY is growing revenue faster at 25.0% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 25/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Butterfly Network Inc

HEALTHCARE · MEDICAL DEVICES · USA

Butterfly Network, Inc., a digital health company, develops, manufactures, and markets ultrasound imaging solutions in the United States and internationally. The company is headquartered in Guilford, Connecticut.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?